The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Currie, C J; Poole, C D; Gale, E A M
Diabetologia; 2009 Sep;52(9):1766-77. PMID: 19572116
School of Medicine, Cardiff University, The Pharma Research Centre, Cardiff MediCentre, Cardiff, CF14 4UJ, UK.


The risk of developing a range of solid tumours is increased in type 2 diabetes, and may be influenced by glucose-lowering therapies. We examined the risk of development of solid tumours in relation to treatment with oral agents, human insulin and insulin analogues.